Recurrence of SRF Post Intravitreal Ranibizumab for Pediatric Choroidal Neovascularisation Secondary to Best Disease.

Abstract

We present five cases of choroidal neovascularization secondary to pediatric Best disease which were treated with two different doses of intravitreal ranibizumab. Optical coherence tomography was used for monitoring of the cases. Three cases had subretinal fibrosis at presentation and two out of these 3 cases required repeat intravitreal ranibizumab at one year follow-up due to recurrence of subfoveal subretinal fluid.

• Authors: Deivanai Subbiah, Hanizasurana Hashim, Fiona Lee Min Chew
• Journal: Ocular immunology and inflammation (Ocul Immunol Inflamm) Vol. 28 Issue 7 Pg. 1149-1151 (Oct 02 2020) ISSN: 1744-5078 [Electronic] England
• PMID: 31509457 (Publication Type: Case Reports, Journal Article)

Chemical References

• Angiogenesis Inhibitors
• VEGFA protein, human
• Vascular Endothelial Growth Factor A
• Ranibizumab

Topics

• Angiogenesis Inhibitors (therapeutic use)
• Child
• Child, Preschool
• Choroidal Neovascularization (diagnosis, drug therapy, etiology)
• Female
• Fluorescein Angiography
• Humans
• Intravitreal Injections
• Male
• Ranibizumab (therapeutic use)
• Recurrence
• Subretinal Fluid (diagnostic imaging)
• Tomography, Optical Coherence
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)
• Visual Acuity (physiology)
• Vitelliform Macular Dystrophy (complications, diagnosis)